Literature DB >> 19147485

Impact of matrix metalloproteinase-2 levels on long-term outcome following pharmacological or electrical cardioversion in patients with atrial fibrillation.

Kimihiko Kato1, Tetsuo Fujimaki, Tetsuro Yoshida, Mitsutoshi Oguri, Kazuhiro Yajima, Takeshi Hibino, Toyoaki Murohara.   

Abstract

AIMS: The aim of this study was to evaluate the role of matrix metalloproteinases (MMPs) for the prediction of long-term maintenance of sinus rhythm (SR) after cardioversion in atrial fibrillation (AF). METHODS AND
RESULTS: The study comprised 102 patients with AF. Pharmacological cardioversion was attempted for a 4-week period with anti-arrhythmic drugs in all patients. Those who failed medication underwent electrical cardioversion. Blood samples for biomarkers and echocardiographic data were obtained at baseline. Thirty-four patients (33.3%) converted to SR by pharmacological (n = 22) and electrical (n = 12) cardioversion and maintained it (SR group). The remaining 68 patients were refractory to the AF (RAF) group including recurrence (n = 22) and unsuccessful treatment (n = 46) after electrical/pharmacological cardioversion. Refractory AF was significantly associated with the duration of AF, hypertension, left atrial diameter, brain natriuretic peptide, MMP-2, and tissue inhibitor of MMP-2. For both multivariable logistic regression analysis and stepwise forward selection procedure, the duration of AF >5 months [odds ratio (OR) 15.32] and MMP-2 >767.0 ng/mL (OR 4.84) were significantly associated with RAF.
CONCLUSION: Our study suggests that elevated MMP-2 and longer AF duration increased the risk for difficulty in restoring SR in AF patients. Stratification of subjects according to the MMP-2 level may therefore be important for the effective management of AF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147485     DOI: 10.1093/europace/eun389

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  10 in total

1.  Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation.

Authors:  Joachim R Ehrlich; Magdalena Kaluzny; Stefan Baumann; Ralf Lehmann; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2011-07-03       Impact factor: 5.460

Review 2.  [Biomarkers and atrial fibrillation : Prediction of recurrences and thromboembolic events after rhythm control management].

Authors:  Jelena Kornej; Katja Schumacher; Daniela Husser; Gerhard Hindricks
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-05-14

3.  Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion.

Authors:  Rupak Mukherjee; Joseph G Akar; J Marcus Wharton; Deborah K Adams; Catherine D McClure; Robert E Stroud; Allison D Rice; Stacia M DeSantis; Francis G Spinale; Michael R Gold
Journal:  J Cardiovasc Transl Res       Date:  2013-05-31       Impact factor: 4.132

4.  Fibrosis in Atrial Fibrillation - Role of Reactive Species and MPO.

Authors:  Kai Friedrichs; Stephan Baldus; Anna Klinke
Journal:  Front Physiol       Date:  2012-06-20       Impact factor: 4.566

5.  Regional heterogeneity in determinants of atrial matrix remodeling and association with atrial fibrillation vulnerability postmyocardial infarction.

Authors:  Mitchel R Stacy; Ben A Lin; Stephanie L Thorn; David C Lobb; Mark W Maxfield; Craig Novack; Kia N Zellars; Lisa Freeburg; Joseph G Akar; Albert J Sinusas; Francis G Spinale
Journal:  Heart Rhythm       Date:  2022-01-21       Impact factor: 6.779

6.  Atrial Fibrillation Progression Is Associated with Cell Senescence Burden as Determined by p53 and p16 Expression.

Authors:  Laurence Jesel; Malak Abbas; Sin-Hee Park; Kensuke Matsushita; Michel Kindo; Hira Hasan; Cyril Auger; Chisato Sato; Patrick Ohlmann; Jean-Philippe Mazzucotelli; Florence Toti; Gilles Kauffenstein; Valérie Schini-Kerth; Olivier Morel
Journal:  J Clin Med       Date:  2019-12-23       Impact factor: 4.241

7.  Drug therapy in atrial fibrillation management: where do we stand in 2010?

Authors:  Gholamreza Davoodi; Mehdi Montazeri
Journal:  J Tehran Heart Cent       Date:  2010-09-30

8.  Exploration of pathophysiological pathways for incident atrial fibrillation using a multiplex proteomic chip.

Authors:  John Molvin; Amra Jujic; Olle Melander; Manan Pareek; Lennart Råstam; Ulf Lindblad; Bledar Daka; Margret Leosdottir; Peter Nilsson; Michael Olsen; Martin Magnusson
Journal:  Open Heart       Date:  2020-03-15

9.  Fibrosis independent atrial fibrillation in older patients is driven by substrate leukocyte infiltration: diagnostic and prognostic implications to patients undergoing cardiac surgery.

Authors:  Christie M Aguiar; Kareem Gawdat; Stephanie Legere; Jean Marshall; Ansar Hassan; Petra C Kienesberger; Thomas Pulinilkunnil; Mathieu Castonguay; Keith R Brunt; Jean-Francois Legare
Journal:  J Transl Med       Date:  2019-12-10       Impact factor: 5.531

Review 10.  Rare Causes of Arterial Hypertension and Thoracic Aortic Aneurysms-A Case-Based Review.

Authors:  Svetlana Encica; Adrian Molnar; Simona Manole; Teodora Filan; Simona Oprița; Eugen Bursașiu; Romana Vulturar; Laura Damian
Journal:  Diagnostics (Basel)       Date:  2021-03-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.